Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.69 |
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1626076 | 1.00 | L3MBTL1 (1.00) | L3MBTL1HRH3ACHEGAASMN1; SMN2 | |
| SCHEMBL7269112 | 1.00 | L3MBTL1 (1.00) | L3MBTL1HRH3ACHEGAASMN1; SMN2 | |
| SCHEMBL9212361 | 1.00 | L3MBTL1 (1.00) | L3MBTL1HRH3ACHEGAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL12494696 | 0.98 | L3MBTL1 (0.97) | L3MBTL1HRH3ACHEGAASMN1; SMN2 | |
| SCHEMBL8903528 | 0.98 | L3MBTL1 (0.97) | L3MBTL1HRH3ACHEGAASMN1; SMN2 | |
| SCHEMBL596252 | 0.98 | L3MBTL1 (0.96) | L3MBTL1HRH3ACHEGAASMN1; SMN2 | |
| SCHEMBL180739 | 0.93 | L3MBTL1 (0.86) | L3MBTL1HRH3ACHEGAASMN1; SMN2 | |
| SCHEMBL24938208 | 0.92 | L3MBTL1 (0.84) | L3MBTL1HRH3ACHEGAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6818365 | 0.91 | L3MBTL1 (0.83) | L3MBTL1HRH3ACHEGAASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL12493760 | 0.88 | L3MBTL1 (0.78) | L3MBTL1HRH3ACHEGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118203558-A | Transdermal patch for treating hypertension | 天津汉瑞药业有限公司 | 2024-06-18 | — | — | CN | claimed |
| JP-55162746-A | — | — | None | — | — | JP | disclosed |
| US-20260102396-A1 | NEW THERAPEUTIC APPROACH TO LUNG DISEASE | UNIV CALIFORNIA (US) | 2026-04-16 | — | — | US | disclosed |
| US-12521389-B2 | Therapeutic approach to lung disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-13 | — | — | US | disclosed |
| US-20220249471-A1 | NEW THERAPEUTIC APPROACH TO LUNG DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-11 | — | — | US | disclosed |
| US-11236087-B2 | Highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-02-01 | — | — | US | disclosed |
| US-11236087-B2 | Highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-02-01 | — | — | US | disclosed |
| US-20210179608-A1 | NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2021-06-17 | — | — | US | disclosed |
| US-20210179608-A1 | NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2021-06-17 | — | — | US | disclosed |
| EP-3704119-A1 | NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2020-09-09 | — | — | EP | disclosed |
| EP-0318798-A2 | Method for the preparation of polyesters and their use as binders or binder components in powder lacques | BAYER AG (DE) | 1989-06-07 | — | — | EP | disclosed |
| EP-0292840-A2 | Cyclic amine derivatives, medicaments containing these compounds and procedure for their preparation | Dr. Karl Thomae GmbH (DE) | 1988-11-30 | — | — | EP | disclosed |
| EP-0021552-B1 | HEXAHYDROAZEPINE, PIPERIDINE AND PYRROLIDINE DERIVATIVES AND PROCESSES FOR PREPARING THEM | JOHN WYETH & BROTHER LIMITED (GB) | 1983-01-26 | — | — | EP | disclosed |
| EP-0003253-B1 | HEXAHYDROAZEPINE, PIPERIDINE AND PYRROLIDINE DERIVATIVES AND PROCESSES FOR MAKING AND USING THEM | JOHN WYETH & BROTHER LIMITED (GB) | 1982-12-22 | — | — | EP | disclosed |
| US-4296029-A | Process for preparing hexahydroazepine, piperidine and pyrrolidine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1981-10-20 | — | — | US | disclosed |
| EP-0021772-A1 | Method of preparing 2-oxo- and 2-unsubstituted-hexahydroazepine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1981-01-07 | — | — | EP | disclosed |
| EP-0021552-A1 | Hexahydroazepine, piperidine and pyrrolidine derivatives and processes for preparing them | JOHN WYETH & BROTHER LIMITED (GB) | 1981-01-07 | — | — | EP | disclosed |
| JP-S55162746-A | PREPARATION OF AMINE DERIVATIVE | GRELAN PHARMACEUT CO LTD | 1980-12-18 | — | — | JP | disclosed |
| US-4197241-A | Hexahydroazepine, piperidine and pyrrolidine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1980-04-08 | — | — | US | disclosed |
| EP-0003253-A1 | Hexahydroazepine, piperidine and pyrrolidine derivatives and processes for making and using them | JOHN WYETH & BROTHER LIMITED (GB) | 1979-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102396-A1 | NEW THERAPEUTIC APPROACH TO LUNG DISEASE | CALCRL, CALCA, P2RY10 | L3MBTL1 1423/4885HRH3 298/4885ACHE 1982/4885 |
| US-20210179608-A1 | NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | CDK2, HCCS, BRD4 | L3MBTL1 4303/4885HRH3 1703/4885ACHE 4330/4885 |
| US-11236087-B2 | Highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | HCCS, BRD4, CDK2 | L3MBTL1 4244/4885HRH3 1121/4885ACHE 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.